Fig 1: APOD, C1QC, PVR, MMP2 might be hub target genes in sarcopenia patients.(A) The result of crossover analysis between 17 coding genes and 9,646 DEGs. (B) The top 29 significant results of the GO enrichment analysis. (C) The significantly enriched KEGG pathway. (D) The interactions between these four genes and 20 genes.
Fig 2: APOD was highly expressed in sarcopenia patients and had diagnostic value for sarcopenia.(A) The area under the ROC curve (AUC) for APOD, C1QC, PVR, MMP2 in the discovery cohort. (B) The area under the ROC curve (AUC) for APOD, C1QC, PVR, MMP2 in the GSE165630 dataset. (C) The area under the ROC curve (AUC) for APOD in the GSE111006, GSE111010, and GSE111016 datasets. (D) The expression of APOD in sarcopenia patients with low muscle mass and normal grip strength compared to healthy individuals in the discovery cohort. (E) The expression of APOD protein in the healthy and sarcopenia samples in the validation cohort. (F) The expression of APOD in sedentary samples and trained samples in the GSE165630 dataset. (G–I) The expression of APOD in healthy controls and sarcopenia samples in the GSE111006, GSE111010, and GSE111016 datasets. *p < 0.05, ***p < 0.001.
Supplier Page from CUSABIO Technology LLC for Human Apolipoprotein D(APOD) ELISA Kit